HTLV-1 and Associated Adult T-cell Leukemia/Lymphoma

Reviews in Clinical and Experimental Hematology

Volumn 7, Issue 4, 2003, Pages 336-361

  Mahieux, Renaud ^a   Gessain, Antoine ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE;

ADULT; AGED; APOPTOSIS; BLOOD TRANSFUSION; CELL CYCLE; CELL IMMORTALIZATION; CELL TRANSFORMATION; CHRONIC DISEASE; CLONE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENETIC STABILITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHUMAN; PROMOTER REGION; PROVIRUS; RETROVIRUS; REVIEW; SOUTHERN BLOTTING; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T CELL LEUKEMIA; T CELL LYMPHOMA; TUMOR CELL; VERTICAL TRANSMISSION; VIRUS GENE; VIRUS TRANSMISSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE PRODUCTS, TAX; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; INFANT, NEWBORN; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 1342283099     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Gessain A. Epidemiology of HTLV-1. In: Human T-cell lymphotropic virus type 1. H.D. Holsberg P (ed), Chichester, pp. 34-63, 1996.
2. Mueller N. The epidemiology of HTLV infection. Cancer Causes Control, 2: 37-52, 1991.
3. Hinuma Y, Komoda H, Chosa T, et al. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int J Cancer, 29: 631-635, 1982.
4. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet, ii: 407-410, 1985.
5. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA, 77: 7415-7419, 1980.
6. Kondo T, Kono H, Miyamoto N, et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers. Int J Cancer, 43: 1061-1064, 1989.
7. Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer, 43: 250-253, 1989.
8. Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer, 45: 237-243, 1990.
9. Yamaguchi K and Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol, 76 Suppl 2: 240-245, 2002.
10. Takahashi K, Takezaki T, Oki T, et al. Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type I. The Mother-to-Child Transmission Study Group. Int J Cancer, 49: 673-677, 1991.
11. Ureta-Vidal A, Angelin-Duclos C, Tortevoye P, et al. Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers. Int J Cancer, 82: 832-836, 1999.
12. Manns A, Cleghorn FR, Falk RT, et al. Role of HTLV-I in development of non-Hodgkin lymphoma in Jamaica and Trinidad and Tobago. The HTLV Lymphoma Study Group. Lancet, 342: 1447-1450, 1993.
13. Gout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med, 322: 383-388, 1990.
14. Taylor GP. The epidemiology of HTLV-I in Europe. J Acquir Immune Defic Syndr Hum Retrovirol, 13: S8-14, 1996.
15. Trejo SR and Ratner L. The HTLV receptor is a widely expressed protein. Virology, 268: 41-48, 2000.
16. Sommerfelt MA, Williams BP, Clapham PR, et al. Human T cell leukemia viruses use a receptor determined by human chromosome 17. Science, 242: 1557-1559, 1988.
17. Nath MD, Ruscetti FW, Petrow-Sadowski C, et al. Regulation of the cell-surface expression of an HTLV-I binding protein in human T cells during immune activation. Blood, 101: 3085-3092, 2003.
18. Manel N, Kinet S, Battini JL, et al. The HTLV receptor is an early T-cell activation marker whose expression requires de novo protein synthesis. Blood, 101: 1913-1918, 2003.
19. Mesnard JM and Devaux C. Multiple control levels of cell proliferation by human T-cell leukemia virus type 1 Tax protein. Virology, 257: 277-284, 1999.
20. Johnson JM, Harrod R, Franchini G. Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1). Int J Exp Pathol, 82: 135-147, 2001.
21. Delamarre L, Rosenberg AR, Pique C, et al. The HTLV-I envelope glycoproteins: structure and functions. J Acquir Immune Defic Syndr Hum Retrovirol, 13: S85-91, 1996.
22. Inoue J, Itoh M, Akizawa T, et al. HTLV-1 Rex protein accumulates unspliced RNA in the nucleus as well as in cytoplasm. Oncogene, 6: 1753-1757, 1991.
23. Albrecht B and Lairmore MD. Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev, 66: 396-406, 2002.
24. Grassmann R, Fleckenstein B, Desrosiers RC. Viral transformation of human T lymphocytes. Adv Cancer Res, 63: 211-244, 1994.
25. Liang MH, Geisbert T, Yao Y, et al. Human T-lymphotropic virus type 1 oncoprotein tax promotes S-phase entry but blocks mitosis. J Virol, 76: 4022-4033, 2002.
26. Pozzatti R, Vogel J, Jay G. The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells. Mol Cell Biol, 10: 413-417, 1990.
27. Iwanaga Y, Tsukahara T, Ohashi T, et al. Human T-cell leukemia virus type 1 tax protein abrogates interleukin-2 dependence in a mouse T-cell line. J Virol, 73: 1271-1277, 1999.
28. Grossman WJ, Kimata JT, Wong FH, et al. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA, 92: 1057-1061, 1995.
29. Yin MJ and Gaynor RB. HTLV-1 21 bp repeat sequences facilitate stable association between Tax and CREB to increase CREB binding affinity. J Mol Biol, 264: 20-31, 1996.
30. Jiang H, Lu H, Schiltz RL, et al. PCAF interacts with tax and stimulates tax transactivation in a histone acetyltransferase-independent manner. Mol Cell Biol, 19: 8136-8145, 1999.
31. Sun SC, Harhaj EW, Xiao G, et al. Activation of I-kappaB kinase by the HTLV type 1 Tax protein: mechanistic insights into the adaptor function of IKKgamma. AIDS Res Hum Retroviruses, 16: 1591-1596, 2000.
32. Pise-Masison CA, Mahieux R, Radonovich M, et al. Insights into the molecular mechanism of p53 inhibition by HTLV type 1 Tax [In Process Citation]. AIDS Res Hum Retroviruses, 16: 1669-1675, 2000.
33. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol, 19: 475-496, 2001.
34. Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene, 22: 5131-5140, 2003.
35. Gatza ML, Watt JC, Marriott SJ. Cellular transformation by the HTLV-I Tax protein, a jack-of-all-trades. Oncogene, 22: 5141-5149, 2003.
36. Jeang KT, Widen SG, Semmes OJt, et al. HTLV-I trans-activator protein, tax, is a transrepressor of the human beta-polymerase gene. Science, 247: 1082-1084, 1990.
37. Suzuki T, Uchida-Toita M, Andoh T, et al. HTLV-1 tax oncoprotein binds to DNA topoisomerase I and inhibits its catalytic activity. Virology, 270: 291-298, 2000.
38. Gabet AS, Mortreux F, Charneau P, et al. Inactivation of hTERT transcription by Tax. Oncogene, 22: 3734-3741, 2003.
39. Yamaguchi K, Seiki M, Yoshida M, et al. The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis of T cell malignancy. Blood, 63: 1235-1240, 1984.
40. Yoshida M, Seiki M, Yamaguchi K, et al. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA, 81: 2534-2537, 1984.
41. Takatsuki K, Yamaguchi K, Matsuoka M. Adult T-cell leukemia. In: Human T Cell Lymphotropic Virus Type 1. H. D. Holsberg P (ed), New York, pp. 219-246, 1996.
42. Takatsuki T. Adult T-cell leukemia in Japan. In: Topics in Hematology. Seno TS and Irino S (eds), Amsterdam, pp. 73-77, 1977.
43. Anonymous. The third nation-wide study on adult T-cell leukemia/lymphoma (ATL) in Japan: characteristic patterns of HLA antigen and HTLV-I infection in ATL patients and their relatives. The T- and B-cell Malignancy Study Group. Int J Cancer, 41: 505-512, 1988.
44. Catovsky D, Greaves MF, Rose M, et al. Adult T-cell lymphoma-leukaemia in Blacks from the West Indies. Lancet, i: 639-643, 1982.
45. Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. J Acquir Immune Defic Syndr Hum Retrovirol, 13: S20-25, 1996.
46. Gerard Y, Lepere JF, Pradinaud R, et al. Clustering and clinical diversity of adult T-cell leukemia/lymphoma associated with HTLV-I in a remote black population of French Guiana. Int J Cancer, 60: 773-776, 1995.
47. Matutes E, Schulz T, Serpa MJ, et al. Report of the second international symposium on HTLV in Brazil. Leukemia, 8: 1092-1094, 1994.
48. Fouchard N, Mahe A, Huerre M, et al. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases. Leukemia, 12: 578-585, 1998.
49. Arisawa K, Soda M, Endo S, et al. Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int J Cancer, 85: 319-324, 2000.
50. Pombo de Oliveira MS, Matutes E, Schulz T, et al. T-cell malignancies in Brazil. Clinicopathological and molecular studies of HTLV-I-positive and -negative cases. Int J Cancer, 60: 823-827, 1995.
51. Takatsuki T. ATL and HTLV-1 related diseases. In: Adult T-cell leukaemia. Takatsuki TK (ed), pp. 1-27, 1994.
52. Shimoyama M. treatment of patients with adult T-cell leukemia-lymphoma: an overview. In: Advances in adult T-cell leukemia and HTLV-1 research. Takatsuki K, et al. (eds), Tokyo, pp. 43-46, 1992.
53. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol, 79: 428-437, 1991.
54. Yamaguchi K, Nishimura H, Kohrogi H, et al. A proposal for smoldering adult T-cell leukemia: a clinicopathologic study of five cases. Blood, 62: 758-766, 1983.
55. Yamaguchi K, Yoshioka R, Kiyokawa T, et al. Lymphoma type adult T-cell leukemia - a clinicopathologic study of HTLV related T-cell type malignant lymphoma. Hematol Oncol, 4: 59-65, 1986.
56. Shimoyama M. Chemotherapy of ATL. In: Adult T-cell Leukaemia. Takatsuki K (ed), pp. 221-236, 1994.
57. Shirono K, Hattori T, Takatsuki K. A new classification of clinical stages of adult T-cell leukemia based on prognosis of the disease. Leukemia, 8: 1834-1837, 1994.
58. Levine PH, Cleghorn F, Manns A, et al. Adult T-cell leukemia/lymphoma: a working point-score classification for epidemiological studies. Int J Cancer, 59: 491-493, 1994.
59. Kamihira S. Hemato-cytological aspects of adult T-cell leukemia. In: Advances in Adult T-Cell Leukemia and HTLV-1 research. H. Y. Takatsuki K and Yoshida M (eds), Tokyo, pp. 17-32, 1992.
60. Shirono K, Hattori T, Hata H, et al. Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia. Blood, 73: 1664-1671, 1989.
61. Uchiyama T, Ishikawa T and Kondo A. Pathophysiology of ATL cells: cell growth characteristics. In: Adult T-cell Leukemia. Takatsuki T. (ed), pp. 181-203, 1994.
62. Suzushima H, Asou N, Nishimura S, et al. Double-negative (CD4- CD8-) T cells from adult T-cell leukemia patients also have poor expression of the T-cell receptor alpha beta/CD3 complex. Blood, 81: 1032-1039, 1993.
63. Ohshima K, Suzumiya J, Sato K, et al. Survival of patients with HTLV-I-associated lymph node lesions. J Pathol, 189: 539-545, 1999.
64. Shimoyama M, Sakurai M, Kamada N. Chromosomal aberrations in adult T-cell leukemia-lymphoma: summary of a karyotype review committee report. In: Advances in Adult T-cell Leukemia and HTLV-1 research. Takatsuki K, et al. (eds), Tokyo, pp. 95-105, 1992.
65. Sakashita A, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult T-cell leukemia. Blood, 79: 477-480, 1992.
66. Chadburn A, Athan E, Wieczorek R, et al. Detection and characterization of human T-cell lymphotropic virus type I (HTLV-I) associated T-cell neoplasms in an HTLV-I nonendemic region by polymerase chain reaction. Blood, 77: 2419-2430, 1991.
67. Tamiya S, Matsuoka M, Etoh K, et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood, 88: 3065-3073, 1996.
68. Tanaka T, Takahashi K, Ideyama S, et al. Demonstration of clonal proliferation of T lymphocytes in early neoplastic disease. Studies with probes for the beta-chain of the T cell receptor and human T cell lymphotropic virus type I. J Am Acad Dermatol, 21: 218-223, 1989.
69. Shimamoto Y, Kobayashi M, Miyamoto Y. Clinical implication of the integration patterns of human T-cell lymphotropic virus type I proviral DNA in adult T-cell leukemia/lymphoma. Leuk Lymphoma, 20: 207-215, 1996.
70. Shimamoto Y, Suga K, Shibata K, et al. Clinical importance of extraordinary integration patterns of human T-cell lymphotropic virus type I proviral DNA in adult T-cell leukemia/lymphoma. Blood, 84: 853-858, 1994.
71. Kato N, Sugawara H, Aoyagi S, et al. Lymphoma-type adult T-cell leukaemia-lymphoma with a bulky cutaneous tumour showing multiple human T-lymphotropic virus-1 DNA integration. Br J Dermatol, 144: 1244-1248, 2001.
72. Furukawa Y, Fujisawa J, Osame M, et al. Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP). Blood, 80: 1012-1016, 1992.
73. Takemoto S, Matsuoka M, Yamaguchi K, et al. A novel diagnostic method of adult T-cell leukemia: monoclonal integration of human T-cell lymphotropic virus type I provirus DNA detected by inverse polymerase chain reaction. Blood, 84: 3080-3085, 1994.
74. Wattel E, Vartanian JP, Pannetier C, et al. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol, 69: 2863-2868, 1995.
75. Cavrois M, Leclercq I, Gout O, et al. Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with Tropical spastic paraparesis/HTLV-1 associated myelopathy. Oncogene, 17: 77-82, 1998.
76. Leclercq I, Mortreux F, Morschhauser F, et al. Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL). Br J Haematol, 105: 743-751, 1999.
77. Tannir N, Riggs S, Velasquez W, et al. Hypercalcemia, unusual bone lesions, and human T-cell leukemia-lymphoma virus in adult T-cell lymphoma. Cancer, 55: 615-619, 1985.
78. Ejima E, Rosenblatt JD, Massari M, et al. Cell-type-specific transactivation of the parathyroid hormone-related protein gene promoter by the human T-cell leukemia virus type I (HTLV-I) tax and HTLV-II tax proteins. Blood, 81: 1017-1024, 1993.
79. Takahashi K, Tanaka T, Fujita M, et al. Cutaneous-type adult T-cell leukemia/lymphoma. A unique clinical feature with monoclonal T-cell proliferation detected by Southern blot analysis. Arch Dermatol, 124: 399-404, 1988.
80. Gessain A, Moulonguet I, Flageul B, et al. Cutaneous type of adult T cell leukemia/lymphoma in a French West Indian woman. Clonal rearrangement of T-cell receptor beta and gamma genes and monoclonal integration of HTLV-I proviral DNA in the skin infiltrate. J Am Acad Dermatol, 23: 994-1000, 1990.
81. Su IJ, Wu YC, Chen YC, et al. Cutaneous manifestations of postthymic T cell malignancies: description of five clinicopathologic subtypes. J Am Acad Dermatol, 23: 653-662, 1990.
82. Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood, 99: 1505-1511, 2002.
83. El-Sabban ME, Merhi RA, Haidar HA, et al. Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood, 99: 3383-3389, 2002.
84. White JD, Zaknoen SL, Kasten-Sportes C, et al. Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma. Cancer, 75:1598-1607, 1995.
85. Gabet AS, Mortreux F, Talarmin A, et al. High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene, 19: 4954-4960, 2000.
86. Plumelle Y, Gonin C, Edouard A, et al. Effect of Strongyloides stercoralis infection and eosinophilia on age at onset and prognosis of adult T-cell leukemia. Am J Clin Pathol, 107: 81-87, 1997.
87. Nakada K, Yamaguchi K, Furugen S, et al. Monoclonal integration of HTLV-I proviral DNA in patients with strongyloidiasis. Int J Cancer, 40: 145-148, 1987.
88. Hermine O, Wattel E, Gessain A, et al. Adult T Cell Leukemia, a review of established and new treatments. BioDrugs, 10: 447-462, 1998.
89. Hermine O, Arnulf B, Bazarbachi A. Treatment of adult-T cell leukemia/lymphoma: clinical results of new therapeutic approaches. AIDS Res Hum Retroviruses, 17: S-29, 2001.
90. Siegel RS, Gartenhaus RB, Kuzel TM. Human T-cell lymphotropic-I-associated leukemia/lymphoma. Curr Treat Options Oncol, 2: 291-300, 2001.
91. Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol, 120: 304-309, 2003.
92. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol, 113: 375-382, 2001.
93. Zhang J, Balestrieri E, Grelli S, et al. Efficacy of 3′-azido 3′deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells. Virus Res, 78: 67-78, 2001.
94. Gill PS, Harrington W, Jr., Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med, 332: 1744-1748, 1995.
95. Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med, 332: 1749-1751, 1995.
96. Hermine O, Allard I, Levy V, et al. A prospective phase II clinical trial with the use od zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J, 3: 276-282, 2002.
97. White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma, 40: 287-294, 2001.
98. Fujimura S, Suzumiya J, Anzai K, et al. Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res, 22: 611-618, 1998.
99. Darwiche N, El-Sabban M, Bazzi R, et al. Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells. Hematol J, 2: 127-135, 2001.
100. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood, 93: 278-283, 1999.
101. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappaB activation. Blood, 96: 2849-2855, 2000.
102. Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood, 101: 4576-4582, 2003.
103. Mahieux R, Pise-Masison C, Gessain A, et al. Arsenic trioxide induces apoptosis in HTLV-1 and HTLV-2 infected cells by a caspase-3 dependent mechanism involving Bcl-2 cleavage. Blood, 98: 3762-3769, 2001.
104. Dewan MZ, Terashima K, Taruishi M, et al. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB. J Virol, 77: 5286-5294, 2003.
105. Tan C and Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res, 62: 1083-1086, 2002.
106. Barmak K, Harhaj E, Grant C, et al. Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology, 308: 1-12, 2003.
107. Slattery JP, Franchini G, Gessain A. Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. Genome Res, 9: 525-540, 1999.
108. Yashiki S, Fujiyoshi T, Arima N, et al. HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes. AIDS Res Hum Retroviuses, 17: 1047-1061, 2001.
109. Furukawa Y, Kubota R, Tara M, et al. Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood, 97: 987-993, 2001.
110. Plancoulaine S, Gessain A, Joubert M, et al. Detection of a major gene predisposing to human T lymphotropic virus type I infection in children among an endemic population of African origin. J Infect Dis, 182: 405-412, 2000.
111. Bartholomew C, Jack N, Edwards J, et al. HTLV-I serostatus of mothers of patients with adult T-cell leukemia and HTLV-I-associated myelopathy/tropical spastic paraparesis. J Hum Virol, 1: 302-305, 1998.
112. Pombo-de-Oliveira MS, Carvalho SM, Borducchi D, et al. Adult T-cell leukemia/lymphoma and cluster of HTLV-I associated diseases in Brazilian settings. Leuk Lymphoma, 42: 135-144, 2001.
113. Hanon E, Hall S, Taylor GP, et al. Abundant tax protein expression in CD4+ T cells infected with human T- cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood, 95: 1386-1392, 2000.
114. Hall WW. Human T cell lymphotropic virus type I and cutaneous T cell leukemia/lymphoma. J Exp Med, 180: 1581-1585, 1994.
115. Capesius C, Saal F, Maero E, et al. No evidence for HTLV-I infection in 24 cases of French and Portuguese mycosis fungoides and Sezary syndrome (as seen in France). Leukemia, 5: 416-419, 1991.
116. Ghosh SK, Abrams JT, Terunuma H, et al. Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T-cell lymphoma. Blood, 84: 2663-2671, 1994.
117. Manca N, Piacentini E, Gelmi M, et al. Persistence of human T cell lymphotropic virus type 1 (HTLV-1) sequences in peripheral blood mononuclear cells from patients with mycosis fungoides. J Med, 180: 1973-1978, 1994.
118. Zucker-Franklin D, Coutavas EE, Rush MG, et al. Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes from patients with mycosis fungoides. Proc Natl Acad Sci USA, 88: 7630-7634, 1991.
119. Bazarbachi A, Soriano V, Pawson R, et al. Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol, 98: 927-933, 1997.
120. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science, 218: 571-573, 1982.
121. Hall WW, Ishak R, Zhu SW, et al. Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. J Acquir Immune Defic Syndr Hum Retrovirol, 13: S204-214, 1996.
122. Gessain A, Mauclere P, Froment A, et al. Isolation and molecular characterization of a human T-cell lymphotropic virus type II (HTLV-II), subtype B, from a healthy Pygmy living in a remote area of Cameroon: an ancient origin for HTLV-II in Africa. Proc Natl. Acad Sci USA, 92: 4041-4045, 1995.
123. Vandamme AM, Bertazzoni U and Salemi M. Evolutionary strategies of human T-cell lymphotropic virus type II. Gene, 261: 171-180, 2000.
124. Ijichi S, Ramundo MB, Takahashi H, et al. In vivo cellular tropism of human T cell leukemia virus type II (HTLV-II). J Exp Med, 176: 293-296, 1992.
125. Rosenblatt JD, Plaeger-Marshall S, Giorgi JV, et al. A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users. Blood, 76: 409-417, 1990.
126. Wang TG, Ye J, Lairmore MD, et al. In vitro cellular tropism of human T cell leukemia virus type 2. AIDS Res Hum Retroviruses, 16: 1661-1668, 2000.
127. Perzova RN, Loughran TP, Dube S, et al. Lack of BLV and PTLV DNA sequences in the majority of patients with large granular lymphocyte leukaemia. Br J Haematol, 109: 64-70, 2000.
128. Poiesz B, Dube D, Dube S, et al. HTLV-II-associated cutaneous T-cell lymphoma in a patient with HIV-1 infection. N Engl J Med, 342: 930-936, 2000.
129. Fouchard N, Flageul B, Bagot M, et al. Lack of evidence of HTLV-I/II infection in T CD8 malignant or reactive lymphoproliferative disorders in France: a serological and/or molecular study of 169 cases. Leukemia, 9: 2087-2092, 1995.
130. Rosenblatt JD, Giorgi JV, Golde DW, et al. Integrated human T-cell leukemia virus II genome in CD8 + T cells from a patient with "atypical" hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders. Blood, 71: 363-369, 1988.
131. Loughran TP, Jr., Coyle T, Sherman MP, et al. Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia. Blood, 80: 1116-1119, 1992.
132. Martin MP, Biggar RJ, Hamlin-Green G, et al. Large granular lymphocytosis in a patient infected with HTLV-II. AIDS Res Hum Retroviruses, 9: 715-719, 1993.
133. Heneine W, Chan WC, Lust JA, et al. HTLV-II infection is rare in patients with large granular lymphocyte leukemia. J Acquir Immune Defic Syndr. 7: 736-737, 1994.
134. Kaplan MH, Hall WW, Susin M, et al. Syndrome of severe skin disease, eosinophilia, and dermatopathic lymphadenopathy in patients with HTLV-II complicating human immunodeficiency virus infection. Am J Med, 91: 300-309, 1991.
135. Zucker-Franklin D, Hooper WC and Evatt BL. Human lymphotropic retroviruses associated with mycosis fungoides: evidence that human T-cell lymphotropic virus type II (HTLV-II) as well as HTLV-I may play a role in the disease. Blood, 80: 1537-1545, 1992.
136. Kazanji M, Tartaglia J, Franchini G, et al. Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus). J Virol, 75: 5939-5948, 2001.
137. Bomford R, Kazanji M, De The G. Vaccine against human T cell leukemia-lymphoma virus type I: progress and prospects. AIDS Res Hum Retroviruses, 12: 403-405, 1996.
138. Matutes E and Catovsky D. ATL of Caribbean origin. In: Adult T-Cell Leukemia. Takatsuki K (ed), pp. 114-138, 1994.